

---

## **Telix Supporting Amgen PSMA-Targeting Therapy Trial**

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 15 September 2021. Telix Pharmaceuticals Limited (ASX: TLX, 'Telix', the 'Company') today announces that it is supplying Illuccix<sup>®</sup> (investigational kit for the preparation of <sup>68</sup>Ga-PSMA-11 injection) to support prostate specific membrane antigen (PSMA) targeted imaging with positron emission tomography (PET) being used in an Amgen Inc. (NASDAQ: AMGN) acapatamab study pursuant to an existing agreement with Invivo LLC, a US-headquartered contract research organisation (CRO) and subsidiary of Konica Minolta.

Acatamab (formerly AMG 160) is a half-life extended (HLE) anti-PSMA x anti-CD3 bispecific T-cell engager (BiTE) immunotherapy being investigated by Amgen for the treatment of prostate cancer.

Telix CEO, Dr. Christian Behrenbruch commented, "This agreement demonstrates both the strength and reliability of Telix's supply chain globally and validates the potential of our Illuccix<sup>®</sup> prostate cancer imaging candidate in support of a wide range of PSMA-targeting therapies."

### **About Illuccix<sup>®</sup>**

Telix's lead investigational product, Illuccix<sup>®</sup> (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. Food and Drug Administration (FDA)<sup>1</sup>, and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA).<sup>2</sup> Telix is also progressing marketing authorisation applications for Illuccix<sup>®</sup> in the European Union<sup>3</sup> and Canada.<sup>4</sup> None of Telix's products have received a marketing authorisation in any jurisdiction.

### **About Telix Pharmaceuticals Limited**

Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit [www.telixpharma.com](http://www.telixpharma.com) and follow Telix on [Twitter](https://twitter.com/TelixPharma) (@TelixPharma) and [LinkedIn](https://www.linkedin.com/company/telix-pharmaceuticals).

### **Telix Investor Relations**

Ms. Kyahn Williamson  
Telix Pharmaceuticals Limited  
SVP Corporate Communications and Investor Relations  
Email: [kyahn.williamson@telixpharma.com](mailto:kyahn.williamson@telixpharma.com)

---

<sup>1</sup> ASX disclosure 24/11/20.

<sup>2</sup> ASX disclosure 14/04/21.

<sup>3</sup> ASX disclosure 1/05/20.

<sup>4</sup> ASX disclosure 16/12/20.

---

### Important Information

*This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "U.S. Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.*